P-gp inhibitors enhances the drug level inside cells by inhibiting the efflux.
My specific question is whether a P-gp inhibitor can be used to enhance the level of rifmapicin in lungs and especially macrophages, if the inhibitor (P-gp) lacks the mycobacterial efflux inhibitory and self antimicrobial potential. As some P-gp inhibitors are developed as bioavailability enhancer of anticancer agents.
There is lack of this type of literature.